Hemostasis News and Research

RSS

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.

ProFibrix initiates Phase III trial with Fibrocaps in spine, liver, vascular and soft tissue surgery

ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.

7 Jun 2012

Clinical data from Boston Scientific endoscopy studies to be presented at DDW

Boston Scientific Corporation announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week (DDW), May 19 – 22 in San Diego.

19 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Vascular Closure Systems completes FastSeal Phase I FIH clinical trial

The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.

9 May 2012

Johnson & Johnson announces acquisition of Bioseal

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

3 May 2012

CSL Behring initiates rVIIa-FP Phase I study in hemophilia A and B

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo.

31 Mar 2012

FDA grants orphan drug designation to CSL Behring's rVIIa-FP

CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin.

16 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012

Haemonetics third quarter net income decreases 8% to $18.3M

Haemonetics Corporation today reported third quarter 2012 GAAP net revenue of $191.2 million, up 8%, net income of $18.3 million, down 8%, and diluted earnings per share of $0.72, down 7%.

31 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

Technoclone, Roche enter strategic alliance to co-develop coagulation assays

Roche announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria, to co-develop a complete range of coagulation assays.

From Roche Sequencing and Life Science 27 Jan 2012

Olympus adds dissolvable sinus spacing and hemostat products to ENT portfolio

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, today announced the addition of a broad line of advanced, dissolvable sinus spacing and hemostat products to its already extensive ENT product portfolio. These products include spacers, foams and powders available in either plant-based or chitosan polysaccharide polymers.

From Evident Corporation - Life Sciences 6 Jan 2012

Pfizer commences PF-05280602 Phase 1 trial in hemophilia A & B

Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.

6 Jan 2012

Positive results from ProFibrix Phase II Fibrocaps clinical trial

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to hemostasis (TTH) and incidence of hemostasis at 3, 5 and 10 minutes, as compared to active control.

5 Jan 2012

Baxter to acquire Synovis

Baxter International Inc. and Synovis Life Technologies, Inc. today announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures.

From Baxter International Inc. 14 Dec 2011

American Society of Hematology 2012 Scholar Awards announced

The American Society of Hematology (ASH) announces the recipients of its 2012 Scholar Awards. The ASH Scholar Awards provide monetary support for fellows and junior faculty pursuing research careers to assist them during the critical period in which they must complete their training and achieve status as an independent investigator.

3 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011

MRG releases 2012 report on US markets for ENT and bronchoscopy devices

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, advances in procedures competing with functional endoscopic sinus surgery (FESS) and nasal packing devices will have a significant positive effect on the ear, nose and throat (ENT) device market in the United States over the next few years.

From Evident Corporation - Life Sciences 28 Nov 2011

ProFibrix Fibrocaps effectively reduces bleeding in liver resection surgery

ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction in mean time to hemostasis (TTH) compared to active control.

15 Nov 2011

Haemonetics second quarter net revenues increase 8% to $179.4 million

Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.

31 Oct 2011